These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 15705272)

  • 1. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Int J STD AIDS; 2005 Jan; 16(1):42-8. PubMed ID: 15705272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
    Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ
    AIDS; 2004 May; 18(8):1169-77. PubMed ID: 15166532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
    Dold L; Ahlenstiel G; Althausen E; Luda C; Schwarze-Zander C; Boesecke C; Wasmuth JC; Rockstroh JK; Spengler U
    PLoS One; 2015; 10(8):e0134158. PubMed ID: 26241854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
    d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
    Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.
    Raboud J; Anema A; Su D; Klein MB; Zakaryan A; Swan T; Palmer A; Hosein S; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg RS; Cooper C;
    HIV Clin Trials; 2012; 13(2):90-102. PubMed ID: 22510356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Demographic, Epidemiological, Immunological, and Clinical Characteristics of Patients with HIV Mono-infection Versus Patients Co-infected with HCV or/and HBV: A Serbian Cohort Study.
    Ranin J; Salemovic D; Brmbolic B; Marinkovic J; Boricic I; Pesic PI; Zerjav S; Stanojevic M; Jevtovic D
    Curr HIV Res; 2018; 16(3):222-230. PubMed ID: 30014804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
    Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
    Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic.
    Sheng WH; Chen MY; Hsieh SM; Hsiao CF; Wang JT; Hung CC; Chang SC
    Clin Infect Dis; 2004 May; 38(10):1471-7. PubMed ID: 15156487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of chronic hepatitis C on HIV-1 disease progression.
    Carlos Martín J; Castilla J; López M; Arranz R; González-Lahoz J; Soriano V
    HIV Clin Trials; 2004; 5(3):125-31. PubMed ID: 15248136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
    Cooper CL; Mills E; Angel JB
    AIDS; 2007 Jan; 21(1):71-6. PubMed ID: 17148970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.